Acetylsalicylic acid is indicated for:
Irrespective of gender only Adults (18 years old or older)
Prophylaxis of deep vein thrombosis and pulmonary embolism.
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adults (18 years old or older)
Prevention of graft occlusion after Coronary Artery Bypass Grafting (CABG). Coronary angioplasty, except during the acute phase (PCI). Prevention of arteriovenous anastomosis for renal dialysis.
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adults (18 years old or older)
History of unstable angina pectoris, except during the acute phase.
Prevention of cardiovascular morbidity in patients suffering from stable angina pectoris.
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adults (18 years old or older)
Secondary prevention of transient ischaemic attacks (TIA) and ischaemic cerebrovascular accidents (CVA), provided intracerebral haemorrhages have been ruled out.
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adults (18 years old or older)
Secondary prevention of myocardial infarction.
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adults (18 years old or older)
Acetylsalicylic acid has analgesic, antipyretic and anti-inflammatory actions. It is indicated for the relief of headache, toothache, migraine, neuralgia, sore throat, dysmenorrhoea and the symptomatic relief of influenza, feverishness, rheumatic pains, sciatica, lumbago, fibrositis, muscular aches and pain.
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adults (18 years old or older)
Migraine with or without aura.
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adults (18 years old or older)
The recommended loading dose is 150-450 mg. The loading dose is administered as soon as possible after onset of symptoms.
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adults (18 years old or older)
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adolescents (12 years - 18 years old)
Acetylsalicylic acid has analgesic and anti-inflammatory actions. It is indicated for the relief of headache, toothache, migraine, neuralgia, sore throat, dysmenorrhoea and the symptomatic relief of influenza, rheumatic pains, sciatica, lumbago, fibrositis, muscular aches and pain.
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adolescents (12 years - 18 years old)
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adolescents (12 years - 18 years old)
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Acetylsalicylic acid is contraindicated in the following cases:
Acetylsalicylic acid is contraindicated in severe renal impairment.
Acetylsalicylic acid is contraindicated in severe cardiac failure.
Acetylsalicylic acid is contraindicated in severe hepatic impairment.
Contraindications for acetylsalicylic acid:
Clinical studies indicate that doses up to 100 mg/day for restricted obstetrical use, which require specialised monitoring, appear safe.
There is insufficient clinical experience regarding the use of doses above 100 mg/day up to 500 mg/day. Therefore, the recommendations below for doses of 500 mg/day and above apply also for this dose range.
Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development.
Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period. During the first and second trimester of pregnancy, acetylsalicylic acid should not be given unless clearly necessary. If acetylsalicylic acid is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.
During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:
the mother and the neonate, at the end of pregnancy, to:
Consequently, acetylsalicylic acid at doses of 100 mg/day and higher is contraindicated during the third trimester of pregnancy.
Acetylsalicylic acid reduces uricosurics effects of probenecid, benzbromarone, sulfinpyrazone. Salicylates reverse the effect of probenecid. The combination should be avoided.
Acetylsalicylic acid should not be used in patients undergoing heparin therapy.
Methotrexate (used at doses >15 mg/week): The combined drugs, methotrexate and acetylsalicylic acid, enhance haematological toxicity of methotrexate due to the decreased renal clearance of methotrexate by acetylsalicylic acid.
Methotrexate (used at doses <15 mg/week): The combined drugs, methotrexate and acetylsalicylic acid, may increase haematological toxicity of methotrexate due to decreased renal clearance of methotrexate by acetylsalicylic acid. Weekly blood count checks should be done during the first weeks of the combination. Enhanced monitoring should take place in the presence of even mildly impaired renal function, as well, as in elderly.
Acetylsalicylic acid is not recommended for use in patients with severe glucose 6-phosphate dehydrogenase deficiency (G6PD) deficiency, as acetylsalicylic acid may cause haemolysis or haemolytic anemia. Factors that may increase the risk of hemolysis are e.g. high dosage, fever or acute infections.
Acetylsalicylic acid should not be used in haemophilia and thrombocytopenia.